system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, METHODS, METHODS, RESULTS. Meshes: Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Fasting, Female, Glucagon, Humans, Insulin, Islets of Langerhans, Male, Middle Aged.
user
Is enhancement of B-cell secretion by blood glucose normalization in type 2 diabetes associated with fasting C-peptide levels? Context: To investigate (i) the variability of beneficial effects achieved by short-term near-normalization of blood glucose in type 2 diabetes patients, and (ii) the relationship of beneficial effects to individual characteristics of diabetes. Arginine-induced insulin and glucagon release tested at two glucose levels before and after 3 days of intensive insulin treatment. The Department of Endocrinology and Diabetology, Karolinska Hospital, Stockholm, Sweden. Type 2 diabetes patients with poor metabolic control sampled from an area-based population of diabetes patients. Levels of fasting blood glucose declined from 15.0 +/- 0.9 to 8.5 +/- 0.7 mmol L-1, C-peptide from 0.81 +/- 0.06 to 0.49 +/- 0.05 nmol L-1 and percent proinsulin (of total IRI) from 7.8 +/- 1.0 to 3.2 +/- 0.6%. At comparable glucose levels arginine-induced insulin secretion was enhanced 46.3 +/- 19.5% (range -36 to 220%). Enhancement correlated with extent of blood glucose normalization and also with fasting C-peptide levels and with overweight. Arginine-induced glucagon secretion was nonsignificantly depressed (17.2 +/- 7.4%, range -59 to 29%). Insulin sensitivity assessed by M:I ratio was increased by a median of 95%.
assistant
In type 2 diabetes patients reversibility of the effects of poor metabolic control on B-cell function is variable. Variability is related to B-cell mass in individual patients with type 2 diabetes. Final Decision: yes